The Technical Analyst
Select Language :
Supernus Pharmaceuticals [SUPN]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Supernus Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Supernus Pharmaceuticals is listed at the  Exchange

1.10% $34.11

America/New_York / 28 mar 2024 @ 16:00


Supernus Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 1 867.01 mill
EPS: 0.0200
P/E: 1 705.50
Earnings Date: May 07, 2024
SharesOutstanding: 54.74 mill
Avg Daily Volume: 0.384 mill
RATING 2024-03-28
A+
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Buy
DE: Neutral
P/E: Strong Buy
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 1 705.50 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
35.70x
Company: PE 1 705.50 | industry: PE 47.78
DISCOUNTED CASH FLOW VALUE
$83.43
(144.60%) $49.32
Date: 2024-03-29
Expected Trading Range (DAY)

$ 32.75 - 35.47

( +/- 3.98%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-21 Bhatt Padmanabh P. Buy 14 491 Common Stock
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Employee Stock Option (Right to Buy)
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Common Stock
2024-03-20 Bhatt Padmanabh P. Sell 400 Employee Stock Option (Right to Buy)
2024-03-20 Bhatt Padmanabh P. Buy 400 Common Stock
INSIDER POWER
38.24
Last 100 transactions
Buy: 802 366 | Sell: 356 762

Forecast: 16:00 - $34.05

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $34.05
Forecast 2: 16:00 - $34.05
Forecast 3: 16:00 - $34.05
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $34.11 (1.10% )
Volume 0.471 mill
Avg. Vol. 0.384 mill
% of Avg. Vol 122.59 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Supernus Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Supernus Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Supernus Pharmaceuticals Inc

Last 10 Buy & Sell Signals For SUPN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$27.85N/AActive
Profile picture for
            Supernus Pharmaceuticals Inc

SUPN

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Last 10 Buy Signals

Date Signal @
SCNSOLUSDMar 29 - 09:59220.06
INVUSDMar 29 - 09:5963.18
SUPERUSDMar 29 - 09:34$1.359
UQCUSDMar 29 - 06:54$7.20
BNBUSDMar 29 - 09:31$615.19
TIMEUSDMar 29 - 09:3232.37
AGLDUSDMar 29 - 09:301.650
MINAUSDMar 29 - 09:29$1.238
CBKUSDMar 29 - 09:281.087
METAMar 28 - 16:00$485.58

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.